The 5‐series F2‐isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein

Among the F2‐isoprostanes, the 15‐ and the 5‐series are currently used as markers of lipid peroxidation in vascular diseases. 15‐F2t‐IsoP (also named iPF2α‐III) exerts a vasoconstriction in most vessels, whereas no data is available concerning 5‐F2t‐IsoP (also named iPF2α‐VI), which is more abundant...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology 2002-03, Vol.135 (5), p.1276-1280
Main Authors: Marlière, Stéphanie, Cracowski, Jean‐Luc, Durand, Thierry, Chavanon, Olivier, Bessard, Janine, Guy, Alexandre, Stanke‐Labesque, Françoise, Rossi, Jean‐Claude, Bessard, Germain
Format: Article
Language:English
Subjects:
5‐F2t‐IsoP
Biological and medical sciences
internal mammary artery
Isoprostane
lipid peroxidation
Medical sciences
saphenous vein
vascular reactivity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among the F2‐isoprostanes, the 15‐ and the 5‐series are currently used as markers of lipid peroxidation in vascular diseases. 15‐F2t‐IsoP (also named iPF2α‐III) exerts a vasoconstriction in most vessels, whereas no data is available concerning 5‐F2t‐IsoP (also named iPF2α‐VI), which is more abundant in plasma. The aim of this study was to determine whether 5‐F2t‐IsoP possess any vascular effects on various vessels including the isolated rat thoracic aorta, the human internal mammary artery and the saphenous vein. In organ baths, 5‐F2t‐IsoP and its 5‐epimer did not affect the basal tone of any vessel, unlike 15‐F2t‐IsoP. These compounds possessed no antagonist effects on 15‐F2t‐IsoP‐induced contractions, No dilator effect was observed in comparison with sodium nitroprusside and acetylcholine on the rat aorta. In conclusion, we show that unlike 15‐F2t‐IsoP, 5‐F2t‐IsoP and its 5‐epimer possess no vasomotor effects and as such are unlikely to be involved in the pathogenesis of vascular diseases. Further studies are required to test whether these mediators may have effects on systems not being measured in the current study. British Journal of Pharmacology (2002) 135, 1276–1280; doi:10.1038/sj.bjp.0704558
ISSN:0007-1188
1476-5381
DOI:10.1038/sj.bjp.0704558